Literature DB >> 16113660

Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.

R Goterris1, J C Hernández-Boluda, A Teruel, C Gómez, M J Lis, M J Terol, M Tormo, C Solano, C Arbona.   

Abstract

The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n = 34); those who underwent second PBSC mobilization (group B, n = 41); those in whom no further harvesting was carried out (group C, n = 30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous transplantation was performed in 30, 23 and 11 patients from groups A, B and C, respectively. Engraftment data and transplantation outcome did not differ significantly between groups A and C. By contrast, group B patients had a faster neutrophil recovery, required less platelet transfusions and experienced less transplant-related morbidity, as reflected by lower antibiotics needs and shorter hospital stays. In conclusion, remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113660     DOI: 10.1038/sj.bmt.1705147

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

2.  Perfusion method for bone marrow cell collection in poor mobilizer lymphoma patient.

Authors:  Shinichiro Mori; Shinya Fujita; Yoshihisa Yamamoto; Ming Li; Shirou Fukuhara; Shosaku Nomura; Susumu Ikehara
Journal:  Int J Hematol       Date:  2011-05-20       Impact factor: 2.490

Review 3.  High dose chemotherapy with stem cell support in the treatment of testicular cancer.

Authors:  Lazar Popovic; Gorana Matovina-Brko; Milica Popovic; Dragana Petrovic; Ana Cvetanovic; Jelena Vukojevic; Darjana Jovanovic
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

4.  Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.

Authors:  I Sánchez-Ortega; S Querol; M Encuentra; S Ortega; A Serra; J M Sanchez-Villegas; J R Grifols; M M Pujol-Balaguer; M Pujol-Bosch; J M Martí; T Garcia-Cerecedo; P Barba; J M Sancho; A Esquirol; J Sierra; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-09-15       Impact factor: 5.483

5.  Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation.

Authors:  Mark A Fiala; Soo Park; Michael Slade; John F DiPersio; Keith E Stockerl-Goldstein
Journal:  Transfusion       Date:  2016-06-17       Impact factor: 3.157

6.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

7.  Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.

Authors:  Jan S Moreb; Donya Salmasinia; Jack Hsu; Wei Hou; Christina Cline; Emma Rosenau
Journal:  Adv Hematol       Date:  2011-11-29

8.  LECT2 drives haematopoietic stem cell expansion and mobilization via regulating the macrophages and osteolineage cells.

Authors:  Xin-Jiang Lu; Qiang Chen; Ye-Jing Rong; Guan-Jun Yang; Chang-Hong Li; Ning-Yi Xu; Chao-Hui Yu; Hui-Ying Wang; Shun Zhang; Yu-Hong Shi; Jiong Chen
Journal:  Nat Commun       Date:  2016-09-06       Impact factor: 14.919

Review 9.  LECT2: A pleiotropic and promising hepatokine, from bench to bedside.

Authors:  Yuan Xie; Kai-Wei Fan; Shi-Xing Guan; Yang Hu; Yi Gao; Wei-Jie Zhou
Journal:  J Cell Mol Med       Date:  2022-06-03       Impact factor: 5.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.